IL6 and ovarian cancer: The aim of our present study was to evaluate the implication of the p110α PI3K subunit in ovarian cancer chemoresistance acquisition, and to evaluate whether the JAK/STAT pathway could mediate resistance to PI3K inhibitors through secretion of IL-6.